Related Experiment Video
Updated: Jul 4, 2026
13:08
Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia
Published on: December 2, 2015
Measuring progression in frontotemporal dementia: implications for therapeutic interventions.
C M Kipps1, P J Nestor, C E Dawson
1Department of Clinical Neurosciences, University of Cambridge, UK.
Neurology
|May 29, 2008
Summary
Frontotemporal dementia (FTD) progression can be monitored using Addenbrooke's Cognitive Examination (ACE) over 1-2 years. This tool aids in assessing therapeutic agents without requiring serial imaging, improving clinical trial efficiency.
Area of Science:
- Neurology
- Cognitive Science
- Clinical Research
Background:
- Frontotemporal dementia (FTD) requires reliable instruments to measure disease progression.
- Accurate assessment tools are crucial for evaluating potential therapeutic agents in FTD.
Purpose of the Study:
- To evaluate the utility of cognitive assessments in tracking FTD progression.
- To determine the effectiveness of Addenbrooke's Cognitive Examination (ACE) as a monitoring tool for FTD.
Main Methods:
- Retrospective review of 50 FTD cases from the Cambridge Early Onset Dementia Clinic database.
- Analysis of Mini-Mental State Examination (MMSE) and ACE scores over time.
- Comparison of cognitive decline in FTD patients with and without initial imaging abnormalities, alongside early Alzheimer's disease (AD) and healthy controls.
Main Results:
- Cognitive decline was evident in FTD patients who had died or showed initial MRI atrophy.
- FTD patients with normal scans exhibited stable cognitive scores, mirroring controls.
- Inclusion of FTD patients with normal scans significantly increases sample size requirements for therapeutic trials.
Conclusions:
- Addenbrooke's Cognitive Examination (ACE) effectively detects FTD progression over 1-2 years without serial imaging.
- ACE is a valuable monitoring tool for FTD clinical trials.
- Trials enrolling FTD subjects with abnormal MR scans require fewer participants to detect treatment effects.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...